What do systematic reviews say?

Vasopressin vs norepinephrine

Vasopressin showed no clear difference in total mortalitya compared with norepinephrine (moderate certainty).

• Vasopressors for hypotensive shock 2016 · Cochrane Headline outcomes only
  RR 0.9 [0.78, 1.03]
  8 studies · 1108 participants
  Moderate

Vasopressin vs placebo to reduce blood loss during myomectomy

Vasopressin showed no clear difference in blood loss (ml) Estimated blood loss during myomectomy compared with placebo to reduce blood loss during myomectomy (moderate certainty).

• Interventions to reduce haemorrhage during myomectomy for fibroids 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 128 participants
  Moderate

Vasopressin vs placebo to reduce blood loss during myomectomy

Vasopressin probably leads to lower need for blood transfusion Participants who received blood transfusion compared with placebo to reduce blood loss during myomectomy (moderate certainty).

• Interventions to reduce haemorrhage during myomectomy for fibroids 2014 · Cochrane Headline outcomes only
  OR 0.15 [0.03, 0.74]
  2 studies · 90 participants
  Moderate

Vasopressin vs placebo to reduce blood loss during myomectomy

Vasopressin showed no clear difference in duration of surgery Operative time compared with placebo to reduce blood loss during myomectomy (moderate certainty).

• Interventions to reduce haemorrhage during myomectomy for fibroids 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 108 participants
  Moderate

Vasopressin receptor antagonists vs placebo or no treatment

It is very uncertain whether vasopressin receptor antagonists changes death compared with placebo or no treatment (very low certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.92, 1.33]
  15 studies · 2330 participants
  Very low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 297 participants
  Very low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 580 participants
  Low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1169 participants
  Low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  21 studies · 2641 participants
  Moderate

Vasopressin receptor antagonists vs placebo or no treatment

Vasopressin receptor antagonists probably leads to higher serum sodium concentration (response) compared with placebo or no treatment (moderate certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 2.49 [1.95, 3.18]
  18 studies · 2104 participants
  Moderate

Vasopressin receptor antagonists vs placebo or no treatment

Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 1.67 [1.16, 2.4]
  14 studies · 2058 participants
  Moderate